CN112385841A - Medicated diet composition for type 2 diabetes and preparation method thereof - Google Patents
Medicated diet composition for type 2 diabetes and preparation method thereof Download PDFInfo
- Publication number
- CN112385841A CN112385841A CN202011328527.9A CN202011328527A CN112385841A CN 112385841 A CN112385841 A CN 112385841A CN 202011328527 A CN202011328527 A CN 202011328527A CN 112385841 A CN112385841 A CN 112385841A
- Authority
- CN
- China
- Prior art keywords
- parts
- diabetes
- namely
- type
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 235000005911 diet Nutrition 0.000 title claims abstract description 36
- 230000037213 diet Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 23
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 244000223760 Cinnamomum zeylanicum Species 0.000 claims abstract description 15
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 15
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 15
- 240000004153 Hibiscus sabdariffa Species 0.000 claims abstract description 15
- 235000001018 Hibiscus sabdariffa Nutrition 0.000 claims abstract description 15
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 15
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 14
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 14
- 244000018436 Coriandrum sativum Species 0.000 claims abstract description 14
- 235000002787 Coriandrum sativum Nutrition 0.000 claims abstract description 14
- 244000025254 Cannabis sativa Species 0.000 claims abstract description 13
- 244000179886 Moringa oleifera Species 0.000 claims abstract description 13
- 235000011347 Moringa oleifera Nutrition 0.000 claims abstract description 13
- 240000000249 Morus alba Species 0.000 claims abstract description 13
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 13
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 12
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 12
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 12
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 12
- 241001633680 Polygonatum odoratum Species 0.000 claims abstract description 12
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims abstract description 9
- 235000011613 Pinus brutia Nutrition 0.000 claims abstract description 9
- 241000018646 Pinus brutia Species 0.000 claims abstract description 9
- 241000219780 Pueraria Species 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 241000208843 Arctium Species 0.000 claims description 13
- 238000002156 mixing Methods 0.000 claims description 11
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- 244000046146 Pueraria lobata Species 0.000 claims description 8
- 238000002791 soaking Methods 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 241000756042 Polygonatum Species 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 2
- 235000007882 dietary composition Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 3
- 210000004369 blood Anatomy 0.000 abstract description 3
- 235000021018 plums Nutrition 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 210000000496 pancreas Anatomy 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 5
- 101001087416 Homo sapiens Tyrosine-protein phosphatase non-receptor type 11 Proteins 0.000 description 4
- 101000617289 Homo sapiens Tyrosine-protein phosphatase non-receptor type 9 Proteins 0.000 description 4
- 102100033019 Tyrosine-protein phosphatase non-receptor type 11 Human genes 0.000 description 4
- 102100021722 Tyrosine-protein phosphatase non-receptor type 9 Human genes 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 description 2
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091006300 SLC2A4 Proteins 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- LLJFMFZYVVLQKT-UHFFFAOYSA-N 1-cyclohexyl-3-[4-[2-(7-methoxy-4,4-dimethyl-1,3-dioxo-2-isoquinolinyl)ethyl]phenyl]sulfonylurea Chemical compound C=1C(OC)=CC=C(C(C2=O)(C)C)C=1C(=O)N2CCC(C=C1)=CC=C1S(=O)(=O)NC(=O)NC1CCCCC1 LLJFMFZYVVLQKT-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108010057186 Insulin Glargine Proteins 0.000 description 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000037831 Polygonatum sibiricum Species 0.000 description 1
- 244000234609 Portulaca oleracea Species 0.000 description 1
- 235000001855 Portulaca oleracea Nutrition 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 229940125528 allosteric inhibitor Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 230000000225 effect on diabetes Effects 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 1
- 229960004346 glimepiride Drugs 0.000 description 1
- 229960003468 gliquidone Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960002869 insulin glargine Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 244000209700 shan ge teng Species 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/30—Boraginaceae (Borage family), e.g. comfrey, lungwort or forget-me-not
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a medicated diet composition for type 2 diabetes, which is prepared from the following raw materials in parts by weight: 1-15 parts of moringa leaves, 1-10 parts of roselle, 1-15 parts of mulberry leaves, 1-30 parts of Chinese yam, 1-15 parts of rhizoma polygonati, 1-12 parts of polygonatum odoratum, 1-15 parts of wild pueraria, 1-12 parts of herba cirsii, 1-20 parts of emblic leafflower fruits, 1-10 parts of immortal grass, 1-12 parts of coriander, 1-15 parts of burdock roots, 1-12 parts of dark plums, 1-6 parts of cinnamon, 1-10 parts of pine pollen and 0.1-1 part of chitosan oligosaccharide. And a preparation method of the medicinal diet composition for treating type 2 diabetes is provided. The medicinal diet composition for treating type 2 diabetes has the advantages of definite curative effect, clear action target and pharmacological effect, wide raw material source, low cost and simple preparation method, and can dissolve turbidity, reduce blood sugar, invigorate spleen, nourish pancreas, and prevent and treat hyperglycemia and type 2 diabetes.
Description
Technical Field
The invention belongs to the technical field of health care products, and particularly relates to a medicated diet dietary therapy composition for type 2 diabetes and a preparation method thereof.
Background
Diabetes is the second most chronic disease with harmfulness second to hypertension, the prevalence rate of type 2 diabetes in China is 10.4%, the prevalence rate of old people over 60 years old reaches more than 20%, and the prevalence rate is in the world 1 st. At present about 63% of patients with type 2 diabetes are not effectively treated. The western medicine mainly comprises insulin and a plurality of oral hypoglycemic drugs for treating diabetes, the clinical effective rate is less than 70%, about 30% of individuals are accompanied by adverse reactions such as severe liver damage, and about 20-30% of patients have drug resistance after 5 years.
Metformin is preferred for patients with obesity and diabetes. The non-obese type 2 insulin-producing insulin-. The diabetes complicated with kidney disease patient preferably selects the gliquidone elderly patient to be stable and safe hypoglycemic drugs, such as alpha-glucosidase inhibitor, glucagon-like peptide-1 (GLP-1) analogue, dipeptidyl peptidase-4 (DPP-4) inhibitor, insulin glargine, etc. Sulfonylurea hypoglycemic agents have hypoglycemic adverse reactions, the blood sugar needs to be closely monitored, and the elderly do not recommend the children patients to use insulin for treating type 1 diabetes; type 2 diabetes mellitus is only approved for metformin (mainly for children over 10 years of age) and is frequently on business, and patients with irregular meals choose to take medicaments (such as glimepiride) 1 time a day conveniently and with good compliance; has strong side effect and undesirable effect.
The diabetes mellitus is recognized earlier in traditional Chinese medicine, and the diabetes mellitus is recorded in Huangdi's classic of internal classic of medicine and Su Wen and the Ling Shu. The traditional Chinese medicine can effectively treat the diabetes and the complications, has exact curative effect on the early-stage state of the diabetes, and achieves the aim of treating the disease. The traditional Chinese medicine is considered to have definite curative effect on diabetes, and besides clinical formulas, Chinese patent medicines are also recommended to be used for preventing and treating hyperglycemia, such as diabetes mellitus tablets, diabetes mellitus capsules, astragalus mongholicus hypoglycemic tablets, radix puerariae and radix scutellariae and the like, but the Chinese patent medicines belong to medicine products, and the medicine-food homologous products have wide application prospects in the aspects of early prevention, medium-term treatment and later-term rehabilitation of diabetes mellitus, and do not have effective related products in the market at present.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a medicinal diet composition for type 2 diabetes and a preparation method thereof.
The invention provides a medicated diet composition for type 2 diabetes, which is prepared from the following raw materials in parts by weight:
1-15 parts of moringa leaves,
1-10 parts of roselle,
1-15 parts of mulberry leaves,
1-30 parts of Chinese yam,
1-15 parts of rhizoma polygonati,
1-12 parts of polygonatum odoratum,
1 to 15 parts of wild pueraria root,
1-12 parts of common cephalanoplos herb,
1-20 parts of emblic leafflower fruit,
1 to 10 parts of magical grass,
1-12 parts of coriander,
1-15 parts of burdock root,
1-12 parts of dark plum fruit,
1-6 parts of cinnamon, namely,
1-10 parts of pine pollen, namely,
0.1-1 part of chitosan oligosaccharide.
And a preparation method of the medicated diet composition for type 2 diabetes, which comprises the following steps:
weighing the raw materials according to the weight parts of the medicinal diet therapy composition for the type 2 diabetes, mixing moringa oleifera leaves, roselle, mulberry leaves, Chinese yam, rhizoma polygonati, polygonatum odoratum, kudzu vine roots, common cephalanoplos herbs, emblic leafflower fruits, immortal grass, coriander, burdock roots, dark plums and cinnamon, adding 10-20 times of water by mass, soaking for 15-60 minutes, heating, refluxing and extracting for 0.5-2 hours, and filtering by a 100-200-mesh sieve to obtain a first extracting solution;
adding 10-20 times of water by mass into the dregs of a decoction, performing reflux extraction for 0.5-2 hours, and filtering by a 100-250-mesh sieve to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding pollen Pini and chitosan oligosaccharide to obtain the medicated diet composition for treating type 2 diabetes.
The medicinal diet composition for treating type 2 diabetes, disclosed by the invention, is an effective prescription formed by an inventor according to clinical practice and clinical needs, and the relationship among related pharmacodynamic components, pharmacodynamic targets and main treatment diseases is determined through biological medicine big data network pharmacological analysis, so that the medicinal diet composition has the characteristics of definite curative effect, convenience in use, clear action targets and pharmacological effects, wide raw material sources, low cost, simple preparation method, high patient compliance and the like, and is suitable for people at the early stage of diabetes and type 2 diabetes patients. Furthermore, the preparation method of the medicinal diet therapy composition for type 2 diabetes is prepared by adopting a specific process, has good effect and low cost, and meets the requirement of industrialized production.
Drawings
Fig. 1 is a network diagram of the association between traditional Chinese medicine raw materials-active ingredients-action targets of a medicated diet composition for type 2 diabetes provided by the embodiment of the invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is described in further detail below with reference to the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The embodiment of the invention provides a medicated diet composition for type 2 diabetes, which is prepared from the following raw materials in parts by weight:
1-15 parts of moringa leaves,
1-10 parts of roselle,
1-15 parts of mulberry leaves,
1-30 parts of Chinese yam,
1-15 parts of rhizoma polygonati,
1-12 parts of polygonatum odoratum,
1 to 15 parts of wild pueraria root,
1-12 parts of common cephalanoplos herb,
1-20 parts of emblic leafflower fruit,
1 to 10 parts of magical grass,
1-12 parts of coriander,
1-15 parts of burdock root,
1-12 parts of dark plum fruit,
1-6 parts of cinnamon, namely,
1-10 parts of pine pollen, namely,
0.1-1 part of chitosan oligosaccharide.
Wherein rutin in folium Mori, puerarin in radix Puerariae and hesperidin in herba Coriandri inhibit inflammatory factors such as TNF alpha, IL-1 beta and NF-kB from releasing, and resist diabetes of rats induced by streptozocin. The rhizoma dioscoreae aqueous extract and active monomers of allantoin, trigonelline, polygonatum polysaccharides in polygonatum odoratum, apigenin in common cephalanoplos herb and the like in the rhizoma dioscoreae aqueous extract improve the activity of antioxidant enzymes, or activate an Nrf2/HO-1 signal channel, so that the diabetes of rats is prevented. In addition, myricetin in the Sendai grass, polygonatum polysaccharide in the Polygonatum sibiricum, puerarin in the Pueraria lobata, cinnamaldehyde in the cinnamon and cinnamic acid can promote islet B cell regeneration and insulin secretion and reduce hyperglycemia by increasing the expression of glucose transporter 4(GLUT 4). Most notably, non-receptor type protein tyrosine phosphatases 9 and 11(protein type phosphotase non-receptor type 9or 11, PTPN9, PTPN11) are important new targets for diabetes. Chebulaic acid in emblic leafflower fruit is a strong allosteric inhibitor of PTPN9 and PTPN11, the IC50 of PTPN9 and PTPN11 is 34nM and 37nM respectively, and chebulaic acid inhibits the activity of PTPN9 and PTPN11 and promotes glucose uptake by activating AMPK pathway, and is considered as a molecular mechanism of chebulaic acid for resisting type 2 diabetes. The network pharmacology research (figure 1) shows that the medicated diet food therapy composition for the type 2 diabetes can intervene in each link of hyperglycemia and diabetes in multiple components, multiple targets, multiple ways and multiple angles, effectively prevent and treat hyperglycemia, relieve relevant symptoms caused by hyperglycemia and synergistically prevent and treat the chronic disease. Due to the size limitations of fig. 1, the designations are in english or abbreviated, with the corresponding references shown in table 1. The medicated diet composition for treating type 2 diabetes is prepared from food-grade raw materials, and has the advantages of safety, effectiveness, low production cost and reliable prevention effect.
TABLE 1
Preferably, the medicated diet composition for type 2 diabetes is prepared from the following raw materials in parts by weight: 8-10 parts of moringa leaves, 5-7 parts of roselle, 8-10 parts of mulberry leaves, 8-10 parts of Chinese yams, 5-7 parts of rhizoma polygonati, 5-7 parts of radix polygonati officinalis, 8-10 parts of wild pueraria, 5-7 parts of herba cirsii, 5-7 parts of emblic leafflower fruits, 4-6 parts of immortal grass, 5-7 parts of coriander, 5-7 parts of burdock roots, 5-7 parts of plum blossom, 2-4 parts of cinnamon, 2-4 parts of pine pollen and 0.4-0.6 part of chitosan oligosaccharide. More specifically, the medicated diet composition for type 2 diabetes is prepared from the following raw materials in parts by weight: 9 parts of moringa leaves, 6 parts of roselle, 9 parts of mulberry leaves, 9 parts of Chinese yam, 6 parts of rhizoma polygonati, 6 parts of polygonatum odoratum, 9 parts of wild kudzu vine roots, 6 parts of common cephalanoplos herbs, 6 parts of emblic leafflower fruits, 5 parts of immortal grass, 6 parts of coriander, 6 parts of burdock roots, 6 parts of plum fruits, 3 parts of cinnamon, 3 parts of pine pollen and 0.5 part of chitosan oligosaccharide.
The specific functions of part of the components are shown in Table 2:
TABLE 2
The embodiment of the invention also provides a preparation method of the medicinal diet composition for treating type 2 diabetes, which comprises the following steps:
weighing the raw materials according to the weight parts of the medicinal diet therapy composition for the type 2 diabetes, mixing moringa oleifera leaves, roselle, mulberry leaves, Chinese yam, rhizoma polygonati, polygonatum odoratum, kudzu vine roots, common cephalanoplos herbs, emblic leafflower fruits, immortal grass, coriander, burdock roots, dark plums and cinnamon, adding 10-20 times of water by mass, soaking for 15-60 minutes, heating, refluxing and extracting for 0.5-2 hours, and filtering by a 100-200-mesh sieve to obtain a first extracting solution;
adding 10-20 times of water by mass into the dregs of a decoction, performing reflux extraction for 0.5-2 hours, and filtering by a 100-250-mesh sieve to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding pollen Pini and chitosan oligosaccharide to obtain the medicated diet composition for treating type 2 diabetes.
Preferably, the raw materials are weighed according to the weight part of the medicinal diet therapy composition for type 2 diabetes, roselle, shenxiancao, fructus cannabis, cassia seed, wild pueraria root, kelp, radish seed, purslane, emblic leafflower fruit, hawthorn and corn stigma are mixed, 10-15 times of water in parts by mass is added for soaking for 20-40 minutes, the mixture is heated, refluxed and extracted for 0.5-2 hours, and filtered through a 100-200-mesh sieve to obtain a first extracting solution;
adding 10-15 times of water by mass into the medicine residues, heating, refluxing and extracting for 0.5-2 hours, and filtering by a 100-200-mesh sieve to obtain a second extracting solution.
More specifically, the medicinal diet composition for treating type 2 diabetes is prepared by concentrating under reduced pressure at 70 ℃ to a relative density of about 1.03, centrifuging, filtering, adding purified water and appropriate flavoring agent, adding pollen Pini and chitosan oligosaccharide, and making into various liquid beverages, oral liquids, mixtures, etc.
Or concentrating the filtrate under reduced pressure to density of about 1.08 to obtain concentrated solution; adding maltodextrin into the concentrated solution, stirring, and spray drying (nozzle inlet air temperature is 150 deg.C, and air outlet temperature is 80 deg.C) to obtain extract powder.
Adding the above spray dried powder, pollen Pini and chitosan oligosaccharide, and mixing; subpackaging with 10g per bag to obtain the solid beverage.
Adding pollen Pini and chitosan oligosaccharide into the spray dried powder, granulating, drying, packaging, and making into granule at a weight of 10 g/bag.
Adopting spray-dried powder, adding appropriate food raw materials such as pollen pini and chitosan oligosaccharide, granulating, drying, and tabletting; making into suitable tablet form.
The final form of the product can be various, including powder, granule, tablet, honeyed pill, soft extract, oral liquid, syrup, etc. In the preparation process, the drying mode can be spray drying, vacuum drying, freeze drying and the like; the granulation method can be dry granulation, wet granulation, one-step granulation and the like.
The method which can be accepted by relevant laws and regulations of pharmacy, food, health products and the like is adopted, the medicinal diet therapy composition for the type 2 diabetes can be extracted, concentrated, dried or crushed, further processed into products, compound effective ingredients are reserved, and the products are prepared into suitable administration forms (including dosage forms of granules, powder, oral liquid, tablets and the like) or food forms such as tablet candies, meal powder, solid beverages and the like, so that the requirements of the market on relevant products are met, and the invention belongs to the protection scope.
The following examples of specific formulation and preparation process are provided to illustrate the above dietary composition for type 2 diabetes and the preparation method thereof.
Example 1:
weighing 9kg of moringa oleifera leaves, 6kg of roselle, 9kg of mulberry leaves, 9kg of Chinese yam, 6kg of rhizoma polygonati, 6kg of polygonatum odoratum, 9kg of kudzu vine roots, 6kg of herba cephalanoploris, 6kg of emblic leafflower fruits, 5kg of immortal grass, 6kg of coriander, 6kg of burdock roots, 6kg of dark plum fruits and 3kg of cinnamon, mixing, adding 15 times of water, soaking for 30 minutes, heating, refluxing and extracting for 1 hour, filtering by a 200-mesh sieve, and adding 12 times of water into dregs, and refluxing and extracting for 1 hour; mixing filtrates, concentrating under reduced pressure to density of about 1.08, adding 6kg of maltodextrin, and spray drying to obtain extract; adding 3kg pollen Pini and 0.5kg chitosan oligosaccharide, mixing, packaging with powder packaging machine, and making into solid beverage 10 g/bag.
Example 2:
100 patients with type 2 diabetes are selected as health care products to take solid beverages prepared by the medicinal diet therapy composition for type 2 diabetes every day for 2-3 times every day; taking one bag of the product each time, adding 100-200 ml of hot water, mixing and stirring until the mixture is dissolved, and then eating. After two weeks of continuous administration, more than 70% of patients have a reduced fasting blood glucose.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention are intended to be included within the scope of the present invention.
Claims (6)
1. A medicated diet composition for type 2 diabetes is characterized by being prepared from the following raw materials in parts by weight:
1-15 parts of moringa leaves,
1-10 parts of roselle,
1-15 parts of mulberry leaves,
1-30 parts of Chinese yam,
1-15 parts of rhizoma polygonati,
1-12 parts of polygonatum odoratum,
1 to 15 parts of wild pueraria root,
1-12 parts of common cephalanoplos herb,
1-20 parts of emblic leafflower fruit,
1 to 10 parts of magical grass,
1-12 parts of coriander,
1-15 parts of burdock root,
1-12 parts of dark plum fruit,
1-6 parts of cinnamon, namely,
1-10 parts of pine pollen, namely,
0.1-1 part of chitosan oligosaccharide.
2. The medicated diet composition for type 2 diabetes mellitus as claimed in claim 1, which is prepared from the following raw materials in parts by weight:
8-10 parts of moringa leaves,
5-7 parts of roselle,
8-10 parts of mulberry leaves,
8-10 parts of Chinese yam,
5-7 parts of rhizoma polygonati,
5-7 parts of polygonatum odoratum,
8-10 parts of wild kudzu-vine root,
5-7 parts of common cephalanoplos herb,
5-7 parts of emblic leafflower fruit,
4-6 parts of Shenxiancao,
5-7 parts of coriander,
5-7 parts of burdock root,
5-7 parts of plum fruit,
2-4 parts of cinnamon, namely cassia bark,
2-4 parts of pine pollen, namely,
0.4-0.6 part of chitosan oligosaccharide.
3. The medicated diet composition for type 2 diabetes mellitus as claimed in claim 2, which is prepared from the following raw materials in parts by weight:
9 parts of moringa leaves, namely,
6 parts of roselle, namely 6 parts of roselle,
9 parts of mulberry leaves, namely 9 parts of,
9 parts of Chinese yam, namely,
6 parts of sealwort, namely 6 parts of sealwort,
6 parts of radix polygonati officinalis,
9 parts of wild kudzu-vine root,
6 parts of common cephalanoplos herb, herba cirsii japonici,
6 parts of emblic leafflower fruit, namely,
5 parts of the root of magical grass,
6 parts of coriander, namely, coriander,
6 parts of burdock root, namely 6 parts of burdock root,
6 parts of plum fruit, namely, plum fruit,
3 parts of cinnamon, namely cinnamon, wherein,
3 parts of pine pollen, namely pine pollen,
0.5 part of chitosan oligosaccharide.
4. A preparation method of a medicated diet composition for type 2 diabetes is characterized by comprising the following steps:
weighing the raw materials according to the weight parts of the medicinal and dietary food composition for type 2 diabetes mellitus according to any one of claims 1 to 3, mixing moringa leaves, roselle, mulberry leaves, Chinese yam, polygonatum rhizome, polygonatum odoratum, kudzu root, common cephalanoplos herb, emblic leafflower fruit, immortal grass, coriander, burdock root, dark plum and cinnamon, adding 10-20 times of water by mass, soaking for 15-60 minutes, heating, refluxing and extracting for 0.5-2 hours, and filtering with 100-200 meshes to obtain a first extracting solution;
adding 10-20 times of water by mass into the dregs of a decoction, performing reflux extraction for 0.5-2 hours, and filtering by a 100-250-mesh sieve to obtain a second extracting solution;
mixing the first extract and the second extract, concentrating, and adding pollen Pini and chitosan oligosaccharide to obtain the medicated diet composition for treating type 2 diabetes.
5. The method for preparing a herbal cuisine dietary therapy composition for type 2 diabetes according to claim 4, wherein moringa oleifera leaves, roselle, mulberry leaves, Chinese yam, polygonatum rhizome, polygonatum odoratum, kudzu vine root, herba cirsii, emblic leafflower fruit, immortal grass, coriander, burdock root, dark plum and cinnamon are mixed, and 10-15 times of water by mass is added for soaking for 20-40 minutes.
6. The preparation method of the dietary composition as medicated diet for type 2 diabetes mellitus as claimed in claim 4, wherein 10-15 times of water by mass is added to the dregs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/139699 WO2022021780A1 (en) | 2020-07-28 | 2020-12-25 | Medicated diet and dietary therapy composition for type 2 diabetes and preparation method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010738320 | 2020-07-28 | ||
CN2020107383202 | 2020-07-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112385841A true CN112385841A (en) | 2021-02-23 |
Family
ID=74607654
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011328527.9A Withdrawn CN112385841A (en) | 2020-07-28 | 2020-11-24 | Medicated diet composition for type 2 diabetes and preparation method thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN112385841A (en) |
WO (1) | WO2022021780A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115530373A (en) * | 2022-10-11 | 2022-12-30 | 重庆深山生物科技有限公司 | Health food suitable for diabetic patients and preparation method thereof |
US11969453B2 (en) * | 2023-06-14 | 2024-04-30 | Nae Woi Korea., Ltd. | Horseradish and cinnamon mixed extract composition for suppression of avian viral epidemic diseases |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090075343A (en) * | 2008-01-04 | 2009-07-08 | (주)케이엠제약 | Chinese medicine compositions for anti-diabetic and manufacture method thereof |
CN101862413B (en) * | 2010-07-09 | 2012-01-18 | 河北联合大学 | Chinese medicinal preparation for treating type-2 diabetes and preparation method thereof |
CN102380051B (en) * | 2010-09-06 | 2013-10-30 | 柯依坤 | Medicinal steamed bread for treating diabetes |
KR20130010922A (en) * | 2011-07-20 | 2013-01-30 | 강현정 | Crude-drug composites for hypoglycemic effect and manufacturing method thereof |
CN103404757B (en) * | 2013-05-27 | 2014-12-24 | 胡安然 | Special diet for hyperglycemia patients |
CN109745453A (en) * | 2019-02-15 | 2019-05-14 | 何利均 | Treat diabetes medicament |
CN110200276B (en) * | 2019-06-27 | 2023-04-07 | 刘东波 | Composition based on traditional Chinese medicine nutrition |
CN111317808A (en) * | 2020-03-04 | 2020-06-23 | 河南爱糖康健康科技股份有限公司 | Hui drug enzyme for improving physique of diabetes patients |
-
2020
- 2020-11-24 CN CN202011328527.9A patent/CN112385841A/en not_active Withdrawn
- 2020-12-25 WO PCT/CN2020/139699 patent/WO2022021780A1/en active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115530373A (en) * | 2022-10-11 | 2022-12-30 | 重庆深山生物科技有限公司 | Health food suitable for diabetic patients and preparation method thereof |
CN115530373B (en) * | 2022-10-11 | 2023-08-15 | 重庆深山生物科技有限公司 | Health food suitable for diabetics and preparation method thereof |
US11969453B2 (en) * | 2023-06-14 | 2024-04-30 | Nae Woi Korea., Ltd. | Horseradish and cinnamon mixed extract composition for suppression of avian viral epidemic diseases |
Also Published As
Publication number | Publication date |
---|---|
WO2022021780A1 (en) | 2022-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106692297B (en) | Composition for assisting in reducing blood sugar and preparation method and application thereof | |
CN102343023B (en) | Medicinal composition and preparation method and application thereof | |
CN104288501A (en) | Blood glucose reducing particle and preparation method thereof | |
CN112385841A (en) | Medicated diet composition for type 2 diabetes and preparation method thereof | |
CN108578544A (en) | A kind of Chinese medicine composition and the preparation method and application thereof with blood sugar reducing function | |
CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
CN101167863B (en) | Proprietary Chinese medicine for treating diabetes and nephrosis and preparing method thereof | |
CN112353850A (en) | Medicated diet food product composition for hyperlipidemia and fatty liver and preparation method thereof | |
CN107801990A (en) | A kind of health food of auxiliary hyperglycemic and preparation method thereof | |
CN111298021A (en) | Traditional Chinese medicine composition for treating functional constipation | |
CN100462085C (en) | Bee product tablets for diabetes and their making method | |
CN114209758A (en) | Traditional Chinese medicine compound composition capable of maintaining blood sugar health level and preparation method and application thereof | |
CN109620913B (en) | Composition for preventing and/or treating obesity and hyperglycemia | |
AU2021106244A4 (en) | Medicinal diet composition for type 2 diabetes and preparation method thereof | |
CN110755601A (en) | Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof | |
CN100355440C (en) | Compound Chinese medicinal preparation for treating type II diabetes and lowering blood sugar and its preparation method | |
CN1541692A (en) | Medicine for treating diabetes and adjusting blood sugar concentration and its preparation | |
CN111803559B (en) | Eggplant peel composition with blood sugar reducing effect and preparation method and application thereof | |
CN116920061B (en) | Traditional Chinese medicine composition for treating hyperglycemia and preparation method thereof | |
CN111759999B (en) | Traditional Chinese medicine composition and application thereof in preparation of medicine for preventing and/or treating diabetes | |
CN101491580A (en) | Combination with blood sugar reducing function and preparation method thereof | |
CN115252729B (en) | Traditional Chinese medicine composition for treating diabetes and application thereof | |
KR20050102017A (en) | Composition using vinegar processed ginseng preparation for treatment and prevention of type Ⅱ diabetes and metabolic syndrome | |
CN107837309B (en) | Composition with auxiliary blood sugar reducing function and preparation method thereof | |
CN116459311A (en) | Traditional Chinese medicine composition for treating type 2 diabetes and extract, preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210223 |